Premium
Bone marrow transplantation for adults with acute leukaemia and 11q23 chromosomal abnormalities
Author(s) -
Forrest,
Mary E. Nevill,
Horsman,
Brockington,
; Fung,
Cynthia L. Toze,
Eibhlin Conneally,
Donna E. Hogge,
Sutherland,
Nantel,
Shepherd,
David Barnett
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.01030.x
Subject(s) - medicine , chemotherapy , transplantation , retrospective cohort study , surgery , bone marrow , gastroenterology
Adults with acute leukaemia and abnormalities of chromosome 11q23 have a poor prognosis when treated with conventional chemotherapy. To determine whether more intensive therapy can improve outcome for patients with this karyotypic finding, a retrospective analysis of all patients with acute leukaemia and 11q23 abnormalities treated at our centre was performed. 12 patients were treated with conventional chemotherapy alone (CC); 20 patients received high‐dose chemo/radiotherapy (HDCT) with autologous (seven patients) or allogeneic (13 patients) bone marrow transplantation (BMT). The treatment‐related mortality was 25% [95% Confidence Interval (CI) 7–69%] for the CC group and 46% (CI 25–73%) for the BMT group ( P = 0.69). Cumulative risk of leukaemia progression was 89% (CI 61–100%) in the CC patients and 38% (CI 12–69%) in the BMT patients ( P = 0.001). The 2‐year event‐free survival for patients treated with CC was 8% (CI 0–31%) and for patients receiving HDCT and BMT was 34% (CI 14–54%) ( P = 0.03). These results confirm that conventional chemotherapy is rarely curative for adults with acute leukaemia and 11q23 abnormalities but that HDCT with BMT can result in long‐term survival in a significant proportion of patients.